ABSTRACT
Detailed attention to echocardiographic image acquisition allowed measurement of overall MR severity grade in 98.4% of the EVEREST I trial patients (2). The importance of this approach cannot be overemphasized, as prior trials had signifi - cant discordance in actual severity as measured by performing institutions and the core laboratory, or lacked a defi nitive protocol for reporting MR severity (3). Translating the detailed and stringent approach used in a clinical trial to practice is akin to the clinical application of core laboratory criteria for determination of stenosis severity in trials of new coronary stents. However, as percutaneous repair methods gain approval and are used more widely, it is imperative that MR severity is accurately assessed to assure that this unique technology is appropriately utilized.
